Gold prices buoyed by tariff fears; US duties on 1-kilo bars spur supply concerns
Investing.com -- Travere Therapeutics, Inc. (NASDAQ:TVTX) reported stronger-than-expected second quarter 2025 financial results on Wednesday, driven by significant growth in FILSPARI sales, sending shares up 4.4% in trading.
The rare disease drugmaker posted a quarterly loss of $0.14 per share, substantially better than analysts’ expectations of a $0.30 per share loss. Revenue surged to $114.4 million, exceeding the consensus estimate of $99.25 million and representing a 119% increase from $52.2 million in the same period last year. The revenue figure included a $17.5 million milestone payment from CSL (OTC:CSLLY) Vifor.
FILSPARI, the company’s treatment for IgA nephropathy (IgAN), generated $71.9 million in U.S. net product sales, representing 165% growth YoY and demonstrating strong commercial momentum with 745 new patient start forms received during the quarter.
"This quarter marked our strongest commercial performance to date, with increased momentum for FILSPARI resulting in significant growth in a dynamic IgAN market," said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics.
The company is awaiting an FDA decision on August 28, 2025, for its supplemental New Drug Application to modify FILSPARI’s REMS requirements, which could potentially broaden access to the treatment. Additionally, Travere is preparing for a potential approval in focal segmental glomerulosclerosis (FSGS), with an FDA target action date of January 13, 2026.
On a non-GAAP adjusted basis, Travere reported net income of $11.9 million, or $0.13 per share, compared to a net loss of $50.1 million, or $0.65 per share, in the second quarter of 2024.
The company ended the quarter with $319.5 million in cash, cash equivalents, and marketable securities, positioning it to continue advancing its pipeline, including restarting enrollment in its pivotal study of pegtibatinase for classical homocystinuria in 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.